Table 2 Selected Ongoing Clinical Trials in patients with KRAS mutant NSCLC
From: KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Agent(s) | Mechanism of action | Phase | Setting | Sponsors | Primary endpoint | Clinical Trial Number |
|---|---|---|---|---|---|---|
MEK162 + erlotinib | MEK inhibitor | I/IB | Second line and beyond | H. Lee Moffitt Cancer Center and Research Institute Novartis | MTD and PFS | NCT01859026 |
Selumetinib + Docetaxel vs. Docetaxel | MEK inhibitor | III | Second line | AstraZeneca | PFS | NCT01933932 |
Momelotinib alone and in combination with Trametinib | MEK inhibitor | Ib | Second line and beyond | Gilead Sciences | DLT and DCR at 8 weeks | NCT02258607 |
Abemaciclib vs. Eroltinib | CDK inhibitor | III | Second line and beyond | Eli Lilly | PFS and OS | NCT02152631 |
Palbociclib (PD-0332991) + PD 0325901 | CDK 4/6 inhibitor + MEK inhibitor | I/II | First line and beyond | Dana-Farber Cancer Institute | MTD and RP2D | NCT02022982 |
Retaspimycin (IPI-504) + EverolimusGI-4000 | Heat Shock Protein 90 Inhibitor | Ib/II | Second line and beyond | Infinity Pharmaceuticals, Inc. | ORR | NCT01427946 |
Defactinib (VS-6063) | FAK inhibitor | II | Second line and beyond | Verastem, Inc | PFS12 in mutational defined cohorts | NCT01951690 |